ORGANIC ACIDS AS GROWTH INHIBITORS OF PATHOLOGICAL CALCIFICATION AND USES THEREOF
In an embodiment of the present disclosure, there is provided a composition for inhibiting calcium oxalate crystal growth. In an embodiment of the present disclosure, there is provided a composition for inhibiting calcium phosphate crystal growth. In some embodiments, such a composition comprises at least one citrate derivative of an organic acid and at least one pharmaceutically acceptable carrier. In another embodiment, the present disclosure relates to a method of controlling calcium oxalate crystal growth in a subject in need thereof. Such a method comprises administering to the subject an effective amount of the aforementioned composition. In another embodiment, the present disclosure pertains to a method of treating kidney stone disorder. Such a method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. In yet another embodiment, the present disclosure relates to a method of treating calcium oxalate stone disease. In an embodiment, the method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition.
1 . A composition for inhibiting calcium oxalate crystal growth comprising:
at least one citrate derivative of an organic acid; and
at least one pharmaceutically acceptable carrier.
2 . The composition of claim 1 , wherein the organic acid that is a citrate derivative is hydroxycitrate.
3 . The composition of claim 1 , wherein the citrate derivative of an organic acid is tricarballylic acid.
4 . The composition of claim 1 , wherein the citrate derivative of an organic acid is isocitrate.
5 . The composition of claim 1 , comprising two citrate derivatives of an organic acid.
6 . The composition of claim 5 , wherein the two citrate derivatives of an organic acid are hydroxycitrate and tricarballylic acid.
7 . The composition of claim 5 , wherein the two citrate derivatives of an organic acid are hydroxycitrate and isocitrate.
8 . The composition of claim 1 , further comprising a urinary protein.
9 . The composition of claim 1 , wherein the composition is in a form suitable for oral administration.
10 . The composition of claim 1 , wherein the composition inhibits growth of the crystals by about 60%.
11 . The composition of claim 1 , wherein the composition inhibits growth of crystals comprising calcium oxalate monohydrate.
12 . The composition of claim 1 , wherein the composition inhibits growth of crystals comprising calcium oxalate dihydrate.
13 . The composition of claim 1 , wherein the composition inhibits growth of crystals comprising calcium oxalate trihydrate.
14 . The composition of claim 1 , wherein the composition inhibits growth of crystals comprising calcium oxalate monohydrate and calcium oxalate dihydrate.
15 . A composition comprising:
at least one citrate derivative of an organic acid; and
at least one pharmaceutically acceptable carrier, wherein the composition inhibits growth of crystals comprising calcium phosphate.
16 . A method of controlling calcium oxalate crystal growth in a subject in need thereof comprising administering to the subject a composition comprising:
at least one citrate derivative of an organic acid; and
at least one pharmaceutically acceptable carrier.
17 . The method of claim 16 , wherein the subject has kidney stone disorder.
18 . The method of claim 16 , wherein the subject has renal calcification disorder.
19 . The method of claim 16 , wherein the subject has biomineralization induced disease.
20 . The method of claim 16 , further comprising administering the composition post lithotripsy.
21 . The method of claim 16 , wherein the organic acid that is a citrate derivative is hydroxycitrate.
22 . The method of claim 16 , wherein the citrate derivative of an organic acid is tricarballylic acid.
23 . The method of claim 16 , wherein the citrate derivative of an organic acid is isocitrate.
24 . The method of claim 16 , wherein the composition comprises two citrate derivatives of an organic acid.
25 . The method of claim 24 , wherein the two citrate derivatives of an organic acid are hydroxycitrate and tricarballylic acid.
26 . The method of claim 24 , wherein the two citrate derivatives of an organic acid are hydroxycitrate and isocitrate.
27 . The method of claim 16 , wherein the composition further comprises a urinary protein.
28 . A method of treating kidney stone disorder comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising:
at least one citrate derivative of an organic acid; and
at least one pharmaceutically acceptable carrier.
29 . The method of claim 28 , wherein the composition further comprises a urinary protein.
30 . A method of treating calcium oxalate stone disease comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising:
at least one citrate derivative of an organic acid; and
at least one pharmaceutically acceptable carrier.
31 . The method of claim 30 , wherein the composition comprises two citrate derivatives of an organic acid.